Zuppas, Veeva Systems president, sells $1.84m in shares

Eleni Nitsa Zuppas, President & Chief of Staff at Veeva Systems Inc (NYSE:VEEV), sold 6,000 shares of Class A Common Stock on October 7, 2025, for approximately $1.84 million. The shares were sold at a weighted average price of $306.6156, with individual sales prices ranging from $300.6155 to $306.6500.

On the same day, Zuppas exercised options to acquire 6,000 shares of Veeva Systems Class A Common Stock at a price of $135.49, for a total value of $812940.

Following these transactions, Zuppas directly owns 25,325 shares of Veeva Systems Inc. For deeper insights into insider trading patterns and 13 additional exclusive ProTips about Veeva Systems, visit InvestingPro.

In other recent news, Bristol Myers Squibb announced its commitment to Veeva Systems’ Vault CRM platform to enhance engagement with healthcare practitioners through AI technology. Gilead Sciences also joined the list of top pharmaceutical companies adopting Veeva’s Vault CRM, further expanding its partnership with the company. These developments are part of Veeva’s recent customer wins, which BNP Paribas Exane highlighted while reiterating its Outperform rating on Veeva Systems with a price target of $320.00. Raymond James also maintained its Outperform rating on Veeva, setting a price target of $340.00, following Gilead’s commitment.

Meanwhile, Salesforce secured AbbVie as its third top 20 pharmaceutical client for CRM solutions, according to Raymond James. This win adds to Salesforce’s previous successes with Pfizer and Takeda in the pharmaceutical sector. These CRM selections underscore the growing trend among pharmaceutical companies to adopt advanced CRM platforms for better customer engagement. Both Veeva Systems and Salesforce continue to strengthen their positions within the life sciences industry through these strategic partnerships.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.